153
Participants
Start Date
April 8, 2025
Primary Completion Date
October 15, 2026
Study Completion Date
December 15, 2026
PLL001 or placebo daily subcutaneous injections
PLL001 consists of the combination of 4 drug substances (DS) each being a linear poly-lysine flexible backbone with an average length of 70 L-lysines linked with 10% of conjugated side chains all being small chain fatty acids (SCFAs) (acetate, butyrate, lactate and propionate). The remaining 90% of the lysine residues are present as bromide salt. PLL001 DP is presented as 20 mL vials containing 16 mL of a sterilised solution for SC injection with the following formula (5× concentration)
RECRUITING
Liverpool Hospital, Liverpool
RECRUITING
Neuroscience Research Australia, Sydney
RECRUITING
Sunshine Coast University Hospital, Birtinya
RECRUITING
Wesley Research Institute, Brisbane
RECRUITING
Gold Coast University Hospital, Southport
RECRUITING
Flinders Medical Centre, Adelaide
RECRUITING
Alfred Health, Melbourne
RECRUITING
Calvary Health Care, Bethlehem, Melbourne
RECRUITING
Monash Medical Centre, Neuroscience Research, Melbourne
RECRUITING
The Perron Institute for Neurological and Translational Science, Perth
PLL TX AUSTRALIA PTY LTD
INDUSTRY